Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2024 07:00 ET | Source: Auron Therapeutics Inc.

Auron Presents New Preclinical Data for Lead Program AUTX-703 Across Multiple Cancer Types

Treatment with AUTX-703 resulted in notable cell differentiation and tumor growth inhibition in various primary cancer models AUTX-703 IND submission on track for late 2024 NEWTON, Mass. , Oct. 24,...
October 11, 2024 08:00 ET | Source: Auron Therapeutics Inc.

Auron Announces Poster Presentation at 2024 PCF Annual Scientific Retreat

NEWTON, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell...
October 09, 2024 08:00 ET | Source: Auron Therapeutics Inc.

Auron to Present AUTX-703 Preclinical Data 2024 ENA Symposium

NEWTON, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell...
August 19, 2024 08:00 ET | Source: Auron Therapeutics Inc.

Auron Presents Preclinical Data at American Chemical Society Annual Meeting

NEWTON, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell...
May 01, 2024 08:00 ET | Source: Auron Therapeutics Inc.

Auron Announces Oral Presentation on Preclinical Data from Proprietary AURIGIN™ Platform at the AI in Biomedicine Keystone Symposia

NEWTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell...
April 09, 2024 16:30 ET | Source: Auron Therapeutics Inc.

Auron Unveils Preclinical Data Supporting its Lead Program and Ability of its AURIGIN™ Platform to Generate Targeted Cancer Therapies at AACR Annual Meeting

Preclinical data from lead program addressing AURIGIN-identified KAT2A/B target showed significant cell state shift and tumor growth inhibition across multiple primary cancer models AURIGIN overview...
March 06, 2024 08:00 ET | Source: Auron Therapeutics Inc.

Auron Announces Poster Presentations at 2024 AACR Annual Meeting

NEWTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic...
February 08, 2024 08:00 ET | Source: Auron Therapeutics Inc.

Auron Selects First Development Candidate for its Portfolio of Next-Generation Targeted Cancer Treatments from its Novel AURIGIN™ Platform

AUTX-703 has demonstrated potent growth inhibition in preclinical models of solid tumors and a hematological malignancy An overview of the Company’s AURIGIN platform to be presented at the American...
August 10, 2023 11:08 ET | Source: Auron Therapeutics Inc.

Auron Strengthens Board of Directors and Leadership Team with Industry Veterans, Victoria Richon, Ph.D. and Christopher Guiffre, J.D., MBA

NEWTON, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Auron Therapeutics, a platform-based, product-driven biotechnology company focused on discovering and developing novel cancer therapies using its...
August 01, 2023 07:30 ET | Source: Auron Therapeutics Inc.

Auron Establishes Premier Scientific Advisory Board to Support the Advancement of its AI-Powered Platform and Pipeline Targeting Cellular Plasticity in Cancer

NEWTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Auron Therapeutics, a platform-based, product-driven biotechnology company focused on developing novel cancer therapies that target cellular...